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Abstract. Although the costs of dengue illness to patients and households have been extensively studied in endemic
populations, international travelers havenotbeen the focusof costing studies. Asglobalization andhuman travel activities
intensify, travelers are increasingly at risk for emerging and reemerging infectious diseases, such as dengue. This
exploratory study aims to investigate the impact and out-of-pocket costs of dengue illness among travelers. We con-
ducted a prospective study in adult travelers with laboratory-confirmed dengue and recruited patients at travel medicine
clinics in eight different countries fromDecember 2013 toDecember 2015.Using a structured questionnaire, we collected
information on patients and their health-care utilization and out-of-pocket expenditures, as well as income and other
financial losses they incurred because of dengue illness. A total of 90 patients participated in the study, most of whom
traveled for tourism (74%) and visited countries in Asia (82%). Although 22% reported hospitalization and 32% receiving
ambulatory care while traveling, these percentages were higher at 39%and 71%, respectively, after returning home. The
out-of-pocket direct and indirect costs of dengue illness were US$421 (SD 744) and US$571 (SD 1,913) per episode,
respectively, averaging to a total out-of-pocket cost of US$992 (SD 2,052) per episode. The study findings suggest that
international travelers incur important direct and indirect costs because of dengue-related illness. This study is the first to
date to investigate the impact and out-of-pocket costs of travel-related dengue illness from the patient’s perspective and
paves the way for future economic burden studies in this population.
INTRODUCTION
The past five decades have seen an unprecedented emer-
gence of epidemic dengue and other arboviral diseases
resulting from the triad of the modern world: urbanization,
globalization, and human mobility.1 The beginning of the
twenty-first century has marked an exponential growth in
long-haul travel, which includes increased travel to dengue-
endemic countries, and this trend is anticipated to extend into
the future.2 Infected travelers can introduce dengue into non-
endemic areas and contribute to its global spread.3–11 With
climate change–associated alterations in the geographic
distribution of Aedes mosquitoes,12 the risk of dengue in-
troduction into Europe and North America has become a re-
ality, as exemplified by the 2012 dengue outbreak in Madeira,
Portugal,6 although theoverall risk of establishment of dengue
in Europe was modeled to be low.13 Large mass gathering
events in dengue-endemic countries, such as the 2014
Fe´de´ration Internationale de Football Association World Cup
and the Carnival in Brazil, now receive international attention
for posing a potential health threat to travelers and to pop-
ulations in non-endemic countries.14,15
Despite the increased ability in risk communication through
global riskmaps16 and pretravel advice on personal protective
measures against mosquito bites,17,18 dengue preventive
measures for travelers are limited, and dengue has emerged
as a major health threat for international travelers.19 Indeed,
the proportion of dengue cases in ill-returned travelers has
increasedmarkedly over the past few decades,20 and dengue
is the second most commonly diagnosed febrile illness after
malaria.21,22 Studies from the GeoSentinel Surveillance Net-
work in travelers with 60 globally distributed clinics on all
continents have found that dengue is the leading cause of
febrile illness among ill travelers returning fromSoutheast Asia
and Latin America and the Caribbean,23–25 and that the pro-
portion of unwell travelers presenting to GeoSentinel sites who
are found to have dengue increases from non-epidemic to epi-
demic years.22Moreover, an alarming increase in dengue attack
rates has been observed in European travelers.26,27 Dengue af-
fects not only tourists8,9,28–30 but also business travelers,31
expatriates,32,33 those visiting friends and relatives,34–37 pediat-
ric travelers,38–40 South–South travelers,41 and migrants.42–44
Infection with any of the four dengue virus serotypes can
result in a wide spectrum of clinical manifestations, ranging
from asymptomatic and pauci-symptomatic mild febrile ill-
ness to severe and fatal hemorrhagic fever and shock.45 Al-
though usually a self-limiting condition lasting about 1 week
and rarely fatal, dengue in travelers is a common reason for
hospitalization25 and can be incapacitating.46,47 A tripling of
hospitalized dengue cases was reported between 2000 and
2007 in ill-returned travelers in the United States.48
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Recuperation can take several weeks because of physical
weakness and depression.49 Rare complications of dengue,
such as optic neuritis50 and hemophagocytic syndrome,51
have also been reported in travelers.
The impact and costs of dengue illness to patients and
households have been extensively studied in dengue-
endemic populations52–55; however, similar studies have
never been performed in international travelers. Yet, the
United Nations World Tourism Organization projected that
about 1.8 billion travelers will cross international borders by
2030, with Asia and the Pacific region, where arboviral infec-
tions are endemic, highlighted as the fastest growing tourism
regions in theworld.56 Dengue illness can pose a considerable
financial burden on international travelers because of the
costs incurred while seeking and receiving medical care at
destination and home country, financial losses resulting from
disruption to travel itineraries of travelers and accompanying
persons, and income losses if the disease persists after trav-
elers return home. Understanding the financial burden of
dengue in travelers is also important in considering the use of
dengue vaccination.57–59 Within the context of a European
Union funded research project on dengue,60,61 we conducted
a prospective study to investigate and characterize the impact
and out-of-pocket costs of travel-acquired dengue illness
from the traveler’s perspective.
MATERIALS AND METHODS
Study design. This prospective study was conducted in
eight major travel or tropical medicine clinics located in Aus-
tralia, Austria, Germany, Israel, Italy, the Netherlands, Swit-
zerland, and the United States within the GeoSentinel and the
TropNet travel medicine networks. Returning travelers pre-
senting to a participating clinic with dengue-related illness
were invited to participate in the study. Enrollment criteria
required that the patient was an adult (18 years or older) with
laboratory-confirmed diagnosis (at destination or home
country) and pertinent international travel history and returned
to the home country no more than 8 weeks before the study
enrollment date. Recruitment occurred any time during acute
infection or up to 8 weeks after illness onset. The recruitment
period was 24 months, from December 2013 to December
2015.
Research procedures.We developed a structured patient
questionnaire for this study, which elicited information about
patient demographic and socioeconomic characteristics, re-
cent travel history and purpose, pretravel health consultation,
dengue episode characteristics, treatment-seeking behavior,
health-care utilization and associated out-of-pocket expen-
ditures at the point of service (at destination and home
country), and incomeandother financial lossesof patients and
accompanying persons, as well as the impact of dengue ill-
ness episodes on work and school life. The questionnaire was
self-administered and was made available to patients in their
native language.
Data collection andmanagement. Patients who provided
informed consent were given the questionnaire with a study
summary information leaflet during consultation at partici-
pating clinics and were asked to complete and return the
questionnaire to the same clinic during a follow-up visit or by
mail using the prepaid envelope provided. Each questionnaire
was reviewed for completeness and discrepancies by site
coordinators in participating clinics. Data were entered into a
Microsoft Access Database (2015, Microsoft Corp, Red-
mond, WA) and analyzed using SAS 9.4 (SAS Institute Inc.,
Cary, NC).
Analytical framework and statistical analysis. Out-of-
pocket expenditures incurredbypatients as a consequenceof
an episode of dengue illness were categorized as direct and
indirect costs. Direct and indirect costs were estimated using
an ingredients-based approach in which patients were asked
to report their out-of-pocket spending in thesecost categories
during the illness episode both at destination and home
country. Direct costs were further divided into two categories:
1) medical costs and 2) nonmedical costs. Direct medical
costs included costs for consultation, admission and dis-
charge, diagnostic investigations, and medications. Direct
nonmedical costs were composed of costs for meals, trans-
portation, and lodging in a non-health facility such as a hotel
while seeking treatment. Indirect costs included loss of in-
come and nonrefundable prepaid travel costs, and travel
costs of accompanying persons during dengue illness. All
cost information was based on self-report. The total cost as-
sociatedwith eachdengueepisodewasobtainedby summing
direct and indirect costs per illness episode.
The total cost per dengue illness episode was estimated
using three different methods to deal with the issue of missing
data. First, we assumed the costs in a given cost category
were directly proportional to the out-of-pocket expenditure
per capita in the home country. We found the proportionality
factor that provided the best fit and used this linear regression
model to impute the missing values (if any) for that cost cat-
egory. Second, the mean cost in each cost category was es-
timated by averaging over all “available” data in that category.
This approach uses all the available values and is called
available-case analysis; the only drawback is that estimates
are computed using different sample bases according to the
pattern of missing data.62 Third and the last, we confined the
analysis to the set of patients with “complete” cost data
and performed the analysis on a limited part of the dataset,
an approach known as complete-case analysis.62 Both
available-case and complete-case analyses are applied
widely, but their use is recommended when the amount of
missing information is limited to ensure that the results are
unbiased and reliable.62 For all three methods, the total cost
per dengue illness episode was estimated by summing over
direct and indirect costs.
We also reported the per-patient direct costs by treatment
setting (hospitalization and ambulatory care) and geographic
location (destination and home country), given the complex
treatment-seeking behavior observed during dengue illness in
the study population. Direct, indirect, and total costs were
presented as means (SD) and expressed in 2015 in U.S. dol-
lars. All costs reported in local currencywereconverted toU.S.
dollars using thedaily exchange rate of theday the respondent
filled out the questionnaire63 and then adjusted for inflation
using theconsumer price index for theUnitedStates if the cost
incurred before 2015.64
Ethics statement.Eachparticipating clinic obtained ethical
approval from their local internal review board before the start
of the study and followed the pertinent guidelines to ensure
patient confidentiality. A signed consent form was obtained
from all participants. Each questionnaire was assigned a
unique patient identification number. Data on patient
1526 TOZAN AND OTHERS
identifiers were stored securely and separately by site coor-
dinators and were inaccessible to unauthorized persons.
Anonymized data were used in this analysis.
RESULTS
Characteristics of study participants and dengue illness
episodes. A total of 90 adult returned travelers with
laboratory-confirmed dengue infection participated in the
study; the median age was 31 years (range: 18–74 years), and
46% of the patients were female. The general characteristics
of the study population are presented in Table 1. Overall, 58%
of the patientswere aged between 18 and 34 years, 32%aged
between 35 and 55 years, and 10%aged 56 or older. Although
more than half (59%) had a college degree or more education,
11% reported having some college degree, 6%aprofessional
degree, and 24% no more than a high school degree. Most
(59%) were employed (part-time, full-time, or self-employed),
19% reported being a student, and 13% indicated “other” for
employment status. There were several patients who were
unemployed,4 retired,2 and full-time homemaker1 in the study
population.
Most patients reported visiting countries in Asia (82%),
followed by countries in Latin America (13%). In this study
population, the top destination of travel was Thailand (40
travelers, 45%). A majority of the patients (68%) reported
visiting only one country, 22%visiting two countries, and10%
visiting three or more countries. Almost three-quarters of the
patients reported traveling for tourism (66 travelers, 74%),
most of whom self-reported to be high budget travelers (40
travelers, 45%),whereas 11%were traveling to visit family and
friends, 7% for business, and 8% for other reasons. The me-
dian duration of travel was 18 days (range: 3–255). The dura-
tion of travel showed some variation by main purpose for
travel, as shown in Table 2. Whereas the median duration of
tourism-related travel was 18 days (3–165), business travelers
stayed for a shorter period of time (median: 11 days and
range: 5–27).
The characteristics of dengue illness episodes are pre-
sented in Table 3. Themeanduration of feverwas 6.2 days (SD
3.0). The patients felt most sick, on average, 2.5 days (SD 2.5)
after the onset of fever. Almost all patients (98%) reported
experiencing general weakness/fatigue. The other two most
commonly reported symptomswere body (muscle/bone) pain
(86%) and headache (72%), followed by joint pain (59%),
nausea (58%), and hypersensitive skin (57%). During dengue
illness, 19 (21%) patients reported being diagnosed with one
or more other diseases, of whom 12 (63%) indicated receiving
additional treatment while being treated for dengue. Only
three patients of 90 were previously diagnosed with dengue,
but none experienced severe complications.
A total of 43 patients (48%) reported having received travel
advice before traveling, of whom just more than half (22 pa-
tients, 51%)sought advice at a travel clinic andmore thanone-
quarter (12 patients, 28%) from a family doctor. Almost all of
these patients (39 patients, 91%) reported receiving specific
advice tousepersonal protectionmeasures to avoidmosquito
bites during consultation. Although only about half of the pa-
tients sought pretravel health consultation, the majority (70
patients, 78%) reported using personal protection measures
TABLE 1
Characteristics of a prospective cohort of 90 travelerswith laboratory-
confirmed dengue
Age (years) 31 (18–74)
Age group (n, %)
18–34 years 52 (58)
35–55 years 29 (32)
³ 56 years 9 (10)
Gender (n, %)
Female 41 (46)
Male 49 (54)
Education (n, %)
College degree or more 53 (59)
Some college degree 10 (11)
Professional degree 5 (6)
High school degree or less 22 (24)
Employment status (n, %)
Employed (full-time, part-time, or self) 53 (59)
Student 17 (19)
Unemployed/retired/full-time homemaker 7 (7)
Other 13 (14)
TABLE 2
Travel characteristics and travel history of study participants
Number of countries visited (n, %)
One country 61 (68)
Two countries 20 (22)
Three or more countries 9 (10)
Region of travel* (%)
Asia 82
Latin America 13
Other (NorthAmerica,Pacific,andAfrica) 5
Main reason for travel† (n, %)
Tourism‡ 66 (74)
High budget 40 (45)
Low budget 26 (29)
Business 6 (7)
Visiting family/friends 10 (11)
Other 7 (8)
Duration of travel by main reason§, days
(median, range)
Tourism** 18 (3–165)
High budget 16 (3–43)
Low budget 23 (3–255)
Business 11 (5–27)
Visiting family/friends 13 (9–248)
* During one trip, several geographic regions might have been visited.
† Main reason for recent travel unknown or unascertainable for one patient.
‡ Type of tourism is based on patient self-report.
§ Travel duration unknown for one patient.
TABLE 3
Characteristics of dengue illness episodes in study participants
Duration of fever*, days (mean, SD) 6.2 (3.0)
Number of dayspatient feltmost sick after
onset of illness, days (mean, SD)
2.5 (2.5)
Previously diagnosedwith dengue† (n,%)
Yes 3 (3)
No 85 (96)
Do not know 1 (1)
Diseasediagnosis other thandengue (n,%)
Diarrhea 5 (26)
Respiratory illness 4 (21)
Malaria 3 (16)
Febrile illness 3 (16)
Dermatological illness 2 (11)
Other 9 (47)
* Fever duration unknown for four patients.
† History of previous dengue diagnosis unknown for one patient.
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during travel. The average spending on personal protection
measures was US$23 (SD 27) in the study population.
Health-care utilization anddirect out-of-pocket costs of
dengue illness. Whereas 37% of the patients reported
seeking care from amedical care provider within 24 hours and
22%within 24–48 hours of onset of illness, 41%waited more
than 48 hours. The majority (61%) had emergency medical
evacuation insurance and paid, on average, US$66 (SD 174)
for the insurance. Only four patients used this service because
of dengue illness, and this small subset of patients incurred a
mean out-of-pocket cost of US$204 (SD 248).
At destination country, less than a quarter of the patients (20
patients, 22%) were hospitalized because of dengue illness,
with amean hospitalization duration of 3.7 (SD2.8) days.None
required medical care in an intensive care unit. Half of these
patients (10 patients, 50%) reported re-hospitalization,
whereas 14 patients (70%) received ambulatory care after
returning home. A total of 29 patients (32%) sought ambula-
tory care while traveling, and the most frequently visited am-
bulatory care facilities were pharmacy (59.3%) and doctor’s
office (55.6%). After returning home, 12 (41%) of these pa-
tients reported hospitalization and 23 (79%) reported re-
ceiving ambulatory care.
At home country, 35 (39%) patients were hospitalized and
spent a mean of 3.1 days (SD 2.2) in the hospital. Only one
patient received medical care in an intensive care unit for
seven nights. More than half of these hospitalized patients (19
patients, 54%) reported also receiving ambulatory care at
home. Themajority (64patients, 71%) sought ambulatory care
after returning home from travel, of whom 14 (22%) reported
hospitalization earlier at the destination country. The most
frequently visited ambulatory facilities were outpatient de-
partment at a hospital (51.2%), the doctor’s office (23.3%),
and health-care clinic (20.9%).
Table 4 presents the utilization of health-care services for
dengue illness in the study population. The mean number of
ambulatory care visits during adengue illness episodewas 4.4
(SD 4.8) and 3.2 (SD 4.3) at destination and home country,
respectively. Using simple regression imputation, the direct
medical and non-medical costs of dengue illness were esti-
mated at US$260 (SD 553) and US$161 (SD 498) per episode,
respectively, averaging to a direct out-of-pocket cost of US
$421 (SD 744) per dengue illness episode.
Table 5 presents the per-patient direct costs of dengue ill-
ness in travelers as per treatment setting and geographic lo-
cation. At destination country, the mean direct medical and
non-medical costs of hospitalization per patient were US$461
(SD 816) and US$152 (SD 202), respectively, averaging to a
direct hospitalization cost of US$592 (SD 901) per patient.
Patients reported spending, on average,US$169 (SD282) and
US$61 (SD 216) for ambulatory care and transportation, re-
spectively, totaling to amean ambulatory care cost of US$230
(SD 408) per patient. At home country, complete out-of-
pocket expenditures during hospitalization were available for
only 27 patients. The mean direct and non-medical costs of
hospitalization were US$24 (SD 69) and US$171 (SD 496) per
patient, respectively, averaging to a total hospitalization cost
of US$195 (SD 556) per patient. A total of 56 of 64 patients
reported out-of-pocket expenditures for ambulatory care at
home country fully. Patients spent, on average, US$134 (SD
394) for ambulatory care andUS$79 (SD49) for transportation,
totaling at a mean ambulatory care cost of US$213 (SD 613)
per patient.
Overall impact and indirect out-of-pocket costs of
dengue illness. Whereas 12 patients (14%) reported cutting
backon travel for amedianof 7days (range: 1–180) becauseof
dengue illness, seven patients (8%) had to postpone returning
home for a median of 8 days (range: 1–63). The great majority
of the patients (63 patients, 72%) reported impact onwork and
school life. Overall, each dengue episode resulted in a mean
loss of 8.2 (SD 5.2) work or school days, whereas 39 patients
(45%) received a mean of 8.3 (SD 4.6) paid work days off.
Overall, 18 patients (20%) reported loss of income because of
dengue illness, 14 patients (17%) reported incurring non-
refundable travel costs, and only eight patients (9%) were
accompanied by a family member or friend during illness ep-
isode and incurred additional travel-related costs. Under re-
gression imputation, the indirect out-of-pocket cost of
dengue illness averaged US$595 (SD 1,908) per episode.
Total out-of-pocket cost of dengue illness. Out-of-
pocket hospitalization costs were missing for eight patients,
out-of-pocket ambulatory costs for eight patients, and income
loss for two patients. In total, 17 of 90 patients were missing
some cost data. Using imputation to infer the missing costs,
the mean total out-of-pocket cost of dengue illness was es-
timated at US$992 (SD 2,052) per episode (Table 6). Under
available-case analysis, the estimatedmean total costwasUS
$993 (SD 2,079) per episode. When we included only the pa-
tientswith complete cost data (n=73), themean total costwas
estimated at US$889 (SD 2,014) per episode. Given the highly
heterogenous cost data and the small number of missing cost
values, we could not test whether the missing data are ran-
domly distributed (a necessary condition for the validity of
available and complete-case analysis62). However, the fact
that all three estimated means were similar increased our
confidence in the results. Table 6 also presents the direct,
TABLE 4
Utilization of health-care services for dengue illness by international
travelers
Health-care utilization Destination country Home country
Hospitalized (n, %) 20 (22) 35 (39)
Duration of hospitalization
(mean, SD)
3.7 (2.8) 3.1 (2.2)*
Visited ambulatory care facility
(n, %)
29 (32)† 64 (71)‡
Number of ambulatory care visits
(mean, SD)
4.4 (4.8) 3.2 (4.3)
* Duration of hospitalization unknown for one patient.
† Visit of ambulatory care facility at destination country unknown for one patient.
‡ Visit of ambulatory care facility at home country unknown for two patients.
TABLE 5
The per-patient direct out-of-pocket costs of dengue illness by
treatment setting and geographic location, 2015 (all costs are
expressed in U.S. dollars)
Direct costs Destination country Home country
Hospitalization (mean, SD) N = 20 patients N = 27 patients
Medical 461 (816) 24 (69)
Nonmedical 152 (202) 171 (496)
Total direct cost 592 (901) 195 (556)
Ambulatory care (mean, SD) N = 29 patients N = 56 patients
Medical 169 (282) 134 (394)
Nonmedical 61 (216) 79 (46)
Total direct cost 230 (408) 213.1 (623)
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indirect, and total costs of dengue illness per episode by type
of care received. Whereas the direct, indirect, and total costs
were similar for patients who sought ambulatory care only (US
$253, SD 422) and hospitalization only (US$254, SD 574), the
total out-of-pocket expenditure was significantly and un-
surprisingly higher when patients received both ambulatory
and hospital care due to dengue illness (US$992, SD 2,052).
Figure 1 depicts the distribution of total out-of-pocket costs
for individual patients,with theestimates using imputation and
complete-case analysis overlaid. The distribution has a spike
at zero, reflecting somepatients reporting no costs for dengue
illness. If plotted on a linear scale, the distribution exhibits a
long right-hand tail. Both features are typical of cost data.65 As
a result of the heavy tail, theSD is roughly twice themean,with
most costs below themean and a fewmuch higher. Plotted on
a logarithmic scale (as in Figure 1), apart from the spike at zero,
the distribution looks roughly lognormal.
Figure 2 displays the direct out-of-pocket medical cost per
dengue illness episode in each study country. The countries
are ordered on the x axis by their 2015 out-of-pocket expen-
diture per capita, where the Netherlands (US$649) had the
lowest and Switzerland (US$2,136) had the highest per capita
expenditure. The solid black lines indicate the median of non-
zero costs, the boxes display the interquartile range, and the
whiskers extend to the lowest and highest values that are
within 1.5 times the interquartile range of the box. This figure
further illustrates the verywide rangeof out-of-pocketmedical
costs incurred by dengue patients in any given health-care
setting.
DISCUSSION
This exploratory study investigated the utilization of health-
care services for dengue-related illness and associated out-
of-pocket health-care spending of international travelers at
thepoint of service at destinationandhomecountry alongwith
their income and travel-related financial losses. The average
total out-of-pocket cost per episode at US$992 is non-trivial
(Table 6), given that almost all patients experienced short-lived
dengue illness and no complications. This mean per-illness
episode cost was, however, estimated across 90 dengue
patients who sought a range of health-care services at a va-
riety of treatment settings from ambulatory care facilities to
hospitals at both destination and home country with varying
health-care systems. There was a large spread in total costs,
with most costs below the mean and a few much higher
(Figure 1). It is important to underscore that the indirect out-of-
pocket cost at US$571 per dengue illness episode accounted
for more than half the total cost, reflecting the substantial fi-
nancial loss incurred by travelers because of changes in
productive activities and travel itineraries as a consequence of
dengue illness.
In comparison, a modeling study, which assessed the
economic value of pretravel health consultation for malaria,
estimated a total out-of-pocket cost of US$3,387 for hospi-
talized patients in the United States.66 This estimate was
based on a range of out-of-pocket medical cost of US$0–US
$5,000 for insured patients in the United States, which is a
health-care setting with notably high patient cost-sharing
TABLE 6
Out-of-pocket health expenditure for dengue illness in international travelers by treatment setting, 2015 (all costs are expressed in U.S. dollars)
Out-of-pocket costs
Ambulatory care only (N = 37 patients)
(mean, SD)
Hospitalization only (N = 12 patients)
(mean, SD)
Ambulatory care and hospitalization (N = 90 patients)
(mean, SD)
Direct cost 182 (313) 141 (475) 421 (744)
Indirect cost 70 (196) 113 (216) 571 (1,913)
Total cost 253 (422) 254 (574) 992 (2,052)
FIGURE 1. Distribution of total out-of-pocket costs per dengue illness episode for individual patients, with the estimates using imputation (purple)
and complete-case (gray) analysis overlaid (all costs are expressed in 2015 U.S. dollars).
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requirements through deductibles, coinsurance, and co-
payments, or similar charges for covered services, among
high-income countries.66 For uninsured patients, the out-of-
pocket direct cost was assumed to be the average direct
medical cost to the health-care payer, which was US$25,250
in 2009.66 The substantial variations in out-of-pocket costs in
any given setting, as illustrated in Figure 2, underscore the
need for a careful assessment of such costs in much larger
study populations by disease severity, treatment setting, type
of provider, health insurance status, and health-care setting.
Moreover, costing studies often vary in methodological ap-
proaches in terms of types of costs measured and how these
costs are quantified, and hence, cost estimates may be in-
consistent or noncomparable within and across countries and
over time.67
We also reported on the per-patient direct costs incurred at
the point of service by treatment setting and geographic lo-
cation (Table 5). Our results indicate a level of out-of-pocket
spending for health care that is not trivial either. Out-of-pocket
medical spending for hospitalization and ambulatory care at
destination country was high and averaged around US$592
and US$230 per patient. Larger proportions of travelers were
hospitalized or received ambulatory care at home country
(39%, 71%, respectively) than destination country (22%,
32%, respectively). Given that almost all patients reported no
complications, it is unclear if all hospitalizations were neces-
sary and appropriate. Although, in the home country, out-of-
pocket medical spending for hospitalization was negligible
(US$24 per patient), it was nontrivial for ambulatory care and
averaged around US$134 per patient. This suggests overall
lower cost-sharing requirements for hospital care than am-
bulatory care across health-care settings.68–70 Our results
also showed that nonmedical costs at destination and home
country contributedconsiderably to thedirect costsof dengue
illness in travelers, averaging US$152 andUS$171 per patient
for hospitalization, and US$61 and US$79 per patient for
ambulatory care, respectively.
Despite the novelty of data presented here, this study was
limited to a small sample of 90 travelers with laboratory-
confirmed dengue who were recruited from an international
network of travel clinics located in eight different countries.
Small sample size precluded an analysis and comparison of
out-of-pocket medical spending for dengue illness by home
country to account for the differences in the health-care sys-
tems, which affect cost-sharing requirements for a given
basket of health services across countries.68 Although most
hospitalized patients reported having health insurance cov-
erage formedical expenditures, they failed to reliably report on
the received or anticipated reimbursement amount. This may
be related to the factors associated with reimbursement
processes depending on the type of health insurance, par-
ticularly for medical expenditures incurred abroad, including
complex reimbursement requirements, lengthy processing
wait times, and payment delays, all of which may even affect
how many claims are successfully filed and accepted. There
seems to be a gap in the published literature in these regards.
We therefore reported on out-of-pocketmedical expenditures
incurred by travelers at the point of service, which might have
overestimated the total out-of-pocket cost for dengue as
some eligible medical expenses might have been later
FIGURE 2. Box plot of direct out-of-pocket medical costs per dengue illness episode by out-of-pocket expenditure per capita spending in each
study country (all costs are expressed in 2015 U.S. dollars).
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reimbursed and absorbed by third-party payers. Although
potentially costly and administratively complex in high-
income countries, this limitation can be overcome if patient-
level data are extracted from or linked to health insurance
information systems.71 It is also important to note that the
payments into insurancepremiumsarenot typically definedas
out-of-pocket spending for an acute illness episode and were
not captured in this study. Similar to other studies, the study
relied on self-reported data, which are subject to error due to
recall bias.72 However, incurred expenditures and losses by
travelers for dengue illness were episodic in nature. Further-
more, the length of recall period was limited by recruiting pa-
tients who returned to their home country not earlier than
8 weeks before the study enrollment date to address this
limitation, although this might have affected patients’ report-
ing on the reimbursement process and amount.
A final limitation of the study is that self-reporting ofmedical
and nonmedical out-of-pocket expenditures was incomplete
for some patients. We used three different methods to handle
missing cost data. Complete-case analysis is the most com-
monly used approach, but it leads to information loss and is
considered inefficient for univariate analysis, for example,
estimation of means.62 Also, the approach relies on the as-
sumption that patients with complete cost data are repre-
sentative of those with missing data, which is often not the
case, leading to biased estimates. Therefore, we also used
available-case analysis and a simple regression imputation,
which yielded similar mean total costs, increasing our confi-
dence in the results.
Dengue disease cases among travelers have been in-
creasing as the overall dengue burden has expanded globally.
Costing studies from the patients’ perspective provide uswith
an understanding of the welfare loss associated with illnesses
and the potential financial benefit of disease prevention. Al-
though such studies fail to measure and value disutility (pain
and suffering) associated with illness, direct medical and
nonmedical expenditures and indirect costs are pivotal in
elucidating patients’ willingness to pay to avoid another sim-
ilar illness episode, and can be compared against the costs of
preventive measures, including vaccination, targeted at this
population and help with their prioritization.
Convincing at-risk populations and decision-makers, such
as national and private health insurance providers and other
third-party payers, of the need for prevention measures al-
ways involves presenting a cogent financial argument. In this
small cohort of 90 patients, 39% reported being hospitalized
at home country for an average of 3.1 days. Hospitalization
costs not only vary across countries but also within a country
based on hospital ownership type (e.g., for-profit, nonprofit,
and public/government). Using an average cost of US$2,271
per inpatient day based on the 2015 Hospital Statistics of
the American Hospital Association,73 which tracks inpatient
health-care delivery in community hospitals open to the
public, each dengue-related hospitalization would cost about
US$7,040 per case in the United States. Using public hospital
cost data, the direct medical cost of a dengue patient to the
health system would be, on average, US$8,357 in Australia
andUS$3,490 in Italy.73 Although these are ballpark estimates
derived from national averages74 and cost data based on
expert opinion,75 theyhighlight the fact that out-of-pocket costs
incurred by patients provide only a partial estimate of the
societal-level economic burden of travel-acquired dengue
illness. This exploratory study is the first to date to investigate
the impact and out-of-pocket costs of travel-acquired dengue
illness in ill-returned travelers, and will aid to develop evidence-
based priorities in travel medicine practice76,77 and pave the
way for future economic burden studies in this population.
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